As reported late last year, the AQUILA trial showed that treatment with daratumumab reduced the risk of progression to ...

The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma ...

In a 6 to 2 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 AQUILA trial do/do not ...

Pieter Sonneveld, MD, PhD, professor of hematology and chair of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, ...

The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.

Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional indi ...

Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025. Shares rise.

Design We quantified and sequenced the bacterial 16S rRNA gene in blood and AT samples (omental, mesenteric and subcutaneous) of 75 subjects with obesity with or without type 2 diabetes (T2D) and used ...

1Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. 2Department of Radiation Oncology, City of Hope Comprehensive Cancer Center, Duarte ...

Patients with newly diagnosed GCA waited an average of 43 days to start subcutaneous tocilizumab, paying an average of $1023 out-of-pocket for the first month of treatment. Patients with newly ...

For people with diabetes who inject insulin, the syringe and needle size can make a big difference in comfort and staying on track with steady blood sugar levels. According to a 2024 statistics ...